Match each patient's clinical presentation with the most appropriate next step in their diagnostic workup and test sequencing, according to established guidelines for pulmonary nodules and lung mass evaluation.
- 68-year-old current smoker with an incidentally discovered 12-mm solid pulmonary nodule; no prior imaging available.Perform positron emission tomography-computed tomography (PET-CT) scan
- 42-year-old never-smoker with a 4-mm solid pulmonary nodule found on a chest CT performed for blunt chest trauma.No routine follow-up chest imaging is indicated
- 58-year-old former smoker with a 7-mm solid pulmonary nodule; a previous chest CT from 36 months ago demonstrates an identical 7-mm nodule in the exact same location.Discontinue further imaging surveillance
- 72-year-old current smoker with a 3.5-cm lung mass and enlarged ipsilateral paratracheal lymph nodes; PET-CT shows avid uptake in both the mass and the nodes.Perform endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
- 55-year-old current smoker with an incidentally discovered 9-mm pure ground-glass (subsolid) pulmonary nodule; no prior imaging available.Schedule follow-up non-contrast chest CT in 6 to 12 months
Answer
The 12-mm solid nodule matches with PET-CT. The 4-mm solid nodule in a low-risk patient requires no routine follow-up. The 7-mm solid nodule stable for 36 months requires discontinuation of surveillance. The PET-avid mediastinal nodes require tissue confirmation via EBUS-TBNA. The 9-mm pure ground-glass nodule requires a follow-up CT in 6 to 12 months.
Diagnostic sequencing for pulmonary abnormalities requires integrating nodule characteristics with staging algorithms. Solid nodules >8 mm require functional imaging (PET-CT). Solid nodules <6 mm in low-risk individuals require no follow-up to minimize unnecessary radiation. Solid nodules stable for >24 months are considered benign, warranting definitive discontinuation of surveillance. Pure ground-glass nodules >6 mm behave indolently and require delayed follow-up at 6-12 months rather than immediate PET-CT. Finally, during clinical staging, PET-avid lymph nodes must always be tissue-sampled (e.g., via EBUS-TBNA) to rule out inflammatory false-positives before determining surgical candidacy.
Step-by-Step Solution
Key Concept
Pulmonary nodule evaluation and lung mass test sequencing relies heavily on nodule size, composition (solid vs. subsolid), patient risk factors, temporal stability, and the necessity of tissue confirmation for metabolically active nodes.
Estimated Time:2m 30s